Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haleon plc is a consumer healthcare company. The Company's product portfolio is divided among five categories: Oral Health; Pain Relief; vitamins, minerals and supplements (VMS); Respiratory Health; Digestive Health, and Other. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax and Centrum. In addition, the Company also has local strategic brands, which include TUMS, ENO, Flonase, ChapStick, Emergen-C, Fenbid, Grand-Pa, and Dr.BEST. The Company operates its business units in three regions: North America; Europe, Middle East, and Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC).

  • Revenue in GBP (TTM)10.86bn
  • Net income in GBP1.06bn
  • Incorporated2021
  • Employees21.00k
  • Location
    Haleon PLCBuilding 5, First Floor, The HeightsBRENTFORD KT13 0NYUnited KingdomGBR
  • Phone+44 193 282 2000
  • Websitehttps://www.haleon.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Recordati Industria Chimica e Farma SpA1.63bn275.11m7.21bn4.30k26.095.2118.694.421.501.508.907.520.54391.745.53--9.1712.8211.8616.3869.4271.0516.8522.480.811415.900.526161.8417.297.55-19.081.5845.876.23
Ipsen SA2.78bn522.50m7.60bn5.74k15.292.559.242.746.747.3234.7540.450.59562.105.27--11.209.9114.7813.8083.2882.0018.8115.231.5847.090.190421.115.249.43-8.2617.050.98543.71
Qiagen NV1.74bn343.79m8.49bn6.18k24.913.0116.564.881.701.708.5814.040.34442.216.03319,685.206.815.048.516.0264.6565.3919.7615.542.0930.330.3494---4.898.60-17.44--3.72--
Croda International Plc2.09bn649.30m9.07bn5.83k13.983.7511.724.344.654.6514.9617.300.60512.435.85358,678.1018.9212.8522.0415.0547.1745.6131.2720.161.4323.800.202148.6310.578.76102.4023.14-0.88175.41
BioMerieux SA3.16bn398.48m10.27bn13.08k25.803.2316.933.253.823.8230.3030.540.73312.335.39274,480.009.009.8711.5713.1655.9756.2112.2712.941.31136.560.121815.686.319.42-24.7413.709.3320.11
Eurofins Scientific SE5.91bn579.75m10.44bn61.38k18.612.489.981.773.312.9233.7324.840.691434.684.92109,355.007.047.708.719.7022.5423.8010.1811.581.228.080.406719.13-0.083417.70-34.7320.1421.8533.03
UCB SA4.86bn369.94m14.21bn8.70k38.441.7315.972.922.162.1528.6947.810.36691.884.82633,919.302.796.233.487.8269.6673.497.6114.760.77029.120.242431.62-4.504.02-60.19-11.0012.162.42
argenx SE333.66m-576.42m16.85bn843.00--7.36--50.49-12.08-12.087.0146.840.13730.17442.94449,360.00-23.71-21.60-26.37-24.3092.83---172.76-188.608.42-80.200.0044---17.4058.50-73.81--204.62--
Merck KGaA19.58bn2.93bn19.26bn64.23k22.152.884.260.98367.647.6451.0959.630.47362.005.49346,120.307.
Genmab A/S1.73bn652.95m20.24bn1.66k30.986.18--11.7383.7283.72221.20419.770.5317--3.158,792,169.0020.1119.2721.4420.51----37.8340.71----0.0213--72.0743.9083.5837.9929.07--
HALEON PLC10.86bn1.06bn29.87bn21.00k28.191.83--2.750.11470.11471.181.77------517,047.60--------60.76--10.31--0.620411.100.3882--13.76---23.74------
Lonza Group AG5.50bn1.07bn35.29bn17.49k32.803.7622.026.4116.3416.3483.69142.660.36812.285.95355,722.007.205.308.636.4839.1839.9019.5715.201.2721.610.173128.4115.056.4780.2712.8432.934.94
Data as of Mar 30 2023. Currency figures normalised to Haleon PLC's reporting currency: UK Pound GBX

Institutional shareholders

9.98%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Dec 2022145.93m1.58%
The Vanguard Group, Inc.as of 03 Mar 2023135.64m1.47%
Norges Bank Investment Managementas of 31 Dec 2022119.24m1.29%
First Eagle Investment Management LLCas of 31 Jan 2023113.48m1.23%
Franklin Mutual Advisers LLCas of 28 Feb 202396.53m1.05%
BlackRock Fund Advisorsas of 01 Mar 202385.87m0.93%
BlackRock Investment Management (UK) Ltd.as of 28 Feb 202367.37m0.73%
BlackRock Advisors (UK) Ltd.as of 01 Mar 202359.96m0.65%
Invesco Advisers, Inc.as of 02 Mar 202350.07m0.54%
TIAA-CREF Investment Management LLCas of 31 Jan 202347.48m0.51%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.